(BDX) Becton Dickinson - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0758871091
Stock: Catheters, Syringes, Infusion, Diagnostics, Surgical
Total Rating 45
Risk 81
Buy Signal -0.67
| Risk 5d forecast | |
|---|---|
| Volatility | 22.1% |
| Relative Tail Risk | -8.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.08 |
| Alpha | -8.62 |
| Character TTM | |
|---|---|
| Beta | 0.560 |
| Beta Downside | 0.776 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.06% |
| CAGR/Max DD | -0.03 |
EPS (Earnings per Share)
Revenue
Description: BDX Becton Dickinson January 29, 2026
Becton, Dickinson & Company (BDX) is a diversified medical-technology firm that designs, manufactures and markets a broad portfolio of products-including IV catheters, drug-delivery and safety systems, laboratory automation, diagnostic reagents, and surgical supplies-served through five operating segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. Its customers span hospitals, clinics, research labs, pharmaceutical manufacturers and the broader public health ecosystem.
Key recent metrics (FY 2025): revenue $25.1 billion (+5.2% YoY), adjusted EPS $9.84 (+7.1% YoY), and a free-cash-flow conversion of 68%. The Connected Care segment grew 9% on a 3-year compound annual growth rate (CAGR) of 5.8%, driven by rising demand for medication-automation and analytics solutions in outpatient settings. A primary sector driver is the aging U.S. population, which is projected to increase hospital admissions for chronic-care procedures by ~1.4% annually through 2030, bolstering demand for BD’s vascular access and infection-prevention products.
For a deeper quantitative assessment, you may find ValueRay’s platform useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.57 > 1.0 |
| NWC/Revenue: 1.95% < 20% (prev 4.82%; Δ -2.87% < -1%) |
| CFO/TA 0.06 > 3% & CFO 3.39b > Net Income 1.76b |
| Net Debt (18.52b) to EBITDA (5.10b): 3.63 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (285.1m) vs 12m ago -1.83% < -2% |
| Gross Margin: 45.76% > 18% (prev 0.45%; Δ 4531 % > 0.5%) |
| Asset Turnover: 40.04% > 50% (prev 37.76%; Δ 2.28% > 0%) |
| Interest Coverage Ratio: 4.65 > 6 (EBITDA TTM 5.10b / Interest Expense TTM 565.0m) |
Altman Z'' 1.91
| A: 0.01 (Total Current Assets 9.19b - Total Current Liabilities 8.76b) / Total Assets 54.84b |
| B: 0.30 (Retained Earnings 16.70b / Total Assets 54.84b) |
| C: 0.05 (EBIT TTM 2.63b / Avg Total Assets 54.75b) |
| D: 0.52 (Book Value of Equity 15.24b / Total Liabilities 29.56b) |
| Altman-Z'' Score: 1.91 = BBB |
Beneish M -3.12
| DSRI: 0.90 (Receivables 2.51b/2.64b, Revenue 21.92b/20.64b) |
| GMI: 0.99 (GM 45.76% / 45.35%) |
| AQI: 0.98 (AQ_t 0.71 / AQ_t-1 0.72) |
| SGI: 1.06 (Revenue 21.92b / 20.64b) |
| TATA: -0.03 (NI 1.76b - CFO 3.39b) / TA 54.84b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of BDX shares?
As of February 15, 2026, the stock is trading at USD 175.89 with a total of 3,167,399 shares traded.
Over the past week, the price has changed by +6.53%, over one month by +11.02%, over three months by +16.53% and over the past year by +1.58%.
Over the past week, the price has changed by +6.53%, over one month by +11.02%, over three months by +16.53% and over the past year by +1.58%.
Is BDX a buy, sell or hold?
Becton Dickinson has received a consensus analysts rating of 3.59.
Therefor, it is recommend to hold BDX.
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 195.4 | 11.1% |
| Analysts Target Price | 195.4 | 11.1% |
| ValueRay Target Price | 195 | 10.9% |
BDX Fundamental Data Overview February 12, 2026
P/E Trailing = 28.0902
P/E Forward = 11.5207
P/S = 2.9848
P/B = 1.9328
P/EG = 0.7733
Revenue TTM = 21.92b USD
EBIT TTM = 2.63b USD
EBITDA TTM = 5.10b USD
Long Term Debt = 16.92b USD (from longTermDebt, last quarter)
Short Term Debt = 2.62b USD (from shortTermDebt, last quarter)
Debt = 19.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.52b USD (from netDebt column, last quarter)
Enterprise Value = 83.94b USD (65.44b + Debt 19.54b - CCE 1.03b)
Interest Coverage Ratio = 4.65 (Ebit TTM 2.63b / Interest Expense TTM 565.0m)
EV/FCF = 31.90x (Enterprise Value 83.94b / FCF TTM 2.63b)
FCF Yield = 3.13% (FCF TTM 2.63b / Enterprise Value 83.94b)
FCF Margin = 12.00% (FCF TTM 2.63b / Revenue TTM 21.92b)
Net Margin = 8.01% (Net Income TTM 1.76b / Revenue TTM 21.92b)
Gross Margin = 45.76% ((Revenue TTM 21.92b - Cost of Revenue TTM 11.89b) / Revenue TTM)
Gross Margin QoQ = 44.63% (prev 47.50%)
Tobins Q-Ratio = 1.53 (Enterprise Value 83.94b / Total Assets 54.84b)
Interest Expense / Debt = 0.55% (Interest Expense 107.0m / Debt 19.54b)
Taxrate = 21.56% (105.0m / 487.0m)
NOPAT = 2.06b (EBIT 2.63b * (1 - 21.56%))
Current Ratio = 1.05 (Total Current Assets 9.19b / Total Current Liabilities 8.76b)
Debt / Equity = 0.77 (Debt 19.54b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 3.63 (Net Debt 18.52b / EBITDA 5.10b)
Debt / FCF = 7.04 (Net Debt 18.52b / FCF TTM 2.63b)
Total Stockholder Equity = 25.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.21% (Net Income 1.76b / Total Assets 54.84b)
RoE = 6.93% (Net Income TTM 1.76b / Total Stockholder Equity 25.35b)
RoCE = 6.22% (EBIT 2.63b / Capital Employed (Equity 25.35b + L.T.Debt 16.92b))
RoIC = 4.61% (NOPAT 2.06b / Invested Capital 44.68b)
WACC = 6.24% (E(65.44b)/V(84.98b) * Re(7.98%) + D(19.54b)/V(84.98b) * Rd(0.55%) * (1-Tc(0.22)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.09%
[DCF Debug] Terminal Value 86.06% ; FCFF base≈2.75b ; Y1≈3.08b ; Y5≈4.09b
Fair Price DCF = 314.3 (EV 107.97b - Net Debt 18.52b = Equity 89.45b / Shares 284.6m; r=6.24% [WACC]; 5y FCF grow 13.83% → 2.90% )
EPS Correlation: 60.25 | EPS CAGR: -2.34% | SUE: -2.35 | # QB: 0
Revenue Correlation: 85.62 | Revenue CAGR: 2.72% | SUE: 2.08 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.78 | Chg30d=-0.553 | Revisions Net=-2 | Analysts=10
EPS current Year (2026-09-30): EPS=12.58 | Chg30d=-2.361 | Revisions Net=-2 | Growth EPS=-12.6% | Growth Revenue=-11.5%
EPS next Year (2027-09-30): EPS=13.68 | Chg30d=-2.205 | Revisions Net=-1 | Growth EPS=+8.7% | Growth Revenue=+2.0%
P/E Forward = 11.5207
P/S = 2.9848
P/B = 1.9328
P/EG = 0.7733
Revenue TTM = 21.92b USD
EBIT TTM = 2.63b USD
EBITDA TTM = 5.10b USD
Long Term Debt = 16.92b USD (from longTermDebt, last quarter)
Short Term Debt = 2.62b USD (from shortTermDebt, last quarter)
Debt = 19.54b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.52b USD (from netDebt column, last quarter)
Enterprise Value = 83.94b USD (65.44b + Debt 19.54b - CCE 1.03b)
Interest Coverage Ratio = 4.65 (Ebit TTM 2.63b / Interest Expense TTM 565.0m)
EV/FCF = 31.90x (Enterprise Value 83.94b / FCF TTM 2.63b)
FCF Yield = 3.13% (FCF TTM 2.63b / Enterprise Value 83.94b)
FCF Margin = 12.00% (FCF TTM 2.63b / Revenue TTM 21.92b)
Net Margin = 8.01% (Net Income TTM 1.76b / Revenue TTM 21.92b)
Gross Margin = 45.76% ((Revenue TTM 21.92b - Cost of Revenue TTM 11.89b) / Revenue TTM)
Gross Margin QoQ = 44.63% (prev 47.50%)
Tobins Q-Ratio = 1.53 (Enterprise Value 83.94b / Total Assets 54.84b)
Interest Expense / Debt = 0.55% (Interest Expense 107.0m / Debt 19.54b)
Taxrate = 21.56% (105.0m / 487.0m)
NOPAT = 2.06b (EBIT 2.63b * (1 - 21.56%))
Current Ratio = 1.05 (Total Current Assets 9.19b / Total Current Liabilities 8.76b)
Debt / Equity = 0.77 (Debt 19.54b / totalStockholderEquity, last quarter 25.28b)
Debt / EBITDA = 3.63 (Net Debt 18.52b / EBITDA 5.10b)
Debt / FCF = 7.04 (Net Debt 18.52b / FCF TTM 2.63b)
Total Stockholder Equity = 25.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.21% (Net Income 1.76b / Total Assets 54.84b)
RoE = 6.93% (Net Income TTM 1.76b / Total Stockholder Equity 25.35b)
RoCE = 6.22% (EBIT 2.63b / Capital Employed (Equity 25.35b + L.T.Debt 16.92b))
RoIC = 4.61% (NOPAT 2.06b / Invested Capital 44.68b)
WACC = 6.24% (E(65.44b)/V(84.98b) * Re(7.98%) + D(19.54b)/V(84.98b) * Rd(0.55%) * (1-Tc(0.22)))
Discount Rate = 7.98% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.09%
[DCF Debug] Terminal Value 86.06% ; FCFF base≈2.75b ; Y1≈3.08b ; Y5≈4.09b
Fair Price DCF = 314.3 (EV 107.97b - Net Debt 18.52b = Equity 89.45b / Shares 284.6m; r=6.24% [WACC]; 5y FCF grow 13.83% → 2.90% )
EPS Correlation: 60.25 | EPS CAGR: -2.34% | SUE: -2.35 | # QB: 0
Revenue Correlation: 85.62 | Revenue CAGR: 2.72% | SUE: 2.08 | # QB: 1
EPS next Quarter (2026-03-31): EPS=2.78 | Chg30d=-0.553 | Revisions Net=-2 | Analysts=10
EPS current Year (2026-09-30): EPS=12.58 | Chg30d=-2.361 | Revisions Net=-2 | Growth EPS=-12.6% | Growth Revenue=-11.5%
EPS next Year (2027-09-30): EPS=13.68 | Chg30d=-2.205 | Revisions Net=-1 | Growth EPS=+8.7% | Growth Revenue=+2.0%